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Mark A. Hlatky, MDO utcomes matter in cardiology. We needreliable data about long-term outcomes toevaluate which treatments work, whether
they do more good than harm, and which patients
beneﬁt the most. The outcomes that matter most are
the ones that patients and their families care about:
death and major complications such as myocardial
infarction (MI) and stroke. (Other patient-centered
outcomes, such as symptoms, functional capacity,
and quality of life, are also important, even though
they are more difﬁcult to ascertain reliably.) The
tremendous progress we have made in treating car-
diovascular disease is the direct result of clinical
research studies that have evaluated treatments
rigorously and followed up patients to document
their clinical outcomes.
Even though there is consensus that documenting
outcomes is important, there is great variation among
clinical research studies in the length of follow-up.
Long-term follow-up seems like a good idea, but
how long? Some conditions may have a clear natural
time scale during which all the key outcomes should
develop and the full effects of treatment ought to
become evident. Acute illnesses have a shorter nat-
ural time scale than chronic diseases, but an acute
illness may have long-lasting effects. An acute MI
develops suddenly, with a narrow time window of
a few hours during which coronary reperfusion is
effective and a subsequent healing period of a few
weeks, but it leaves permanent damage that may
have long-term sequelae (e.g., susceptibility to late*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the Stanford University School of Medicine, Stanford, California.
Dr. Hlatky has reported that he has no relationships relevant to the
contents of this paper to disclose.arrhythmia or heart failure). Also, the underlying
coronary atherosclerosis remains and provides the
substrate for a future cycle of acute occlusion and
recurrent MI. So what is the “natural time scale” for
assessing outcomes of an acute MI? Large-scale clin-
ical trials generally measure primary outcomes at 4 to
6 weeks, which is long enough to identify short-term
treatment effects yet short enough to be reasonably
practical: a short-term time frame to assess an acute
disease treated with a 1-time therapy.
But is a few weeks long enough to assess the results
of therapy for acute MI? Timely reperfusion might
provide long-term beneﬁts by limiting myocardial
damage, but implantation of a coronary stent may
have long-term consequences, such as stent throm-
bosis. We can’t document late effects of treatment,
either good or bad, unless we follow up patients over
the long term. Unfortunately, we usually do not.
Why is long-term follow-up important? Many
treatments have effects that will not be immediately
evident, so short-term follow-up would not capture
the full lifecycle of these therapies. For instance,
implanted devices may fail after a few years, and
drug therapy might take time to alter the natural
history of disease; the survival curves for niacin and
placebo in the Coronary Drug Project began to sepa-
rate only after 8 years of follow-up (1). In contrast,
10-year follow-up studies of patients treated with
thrombolysis for acute MI showed parallel survival
curves after 1 year, with no evidence of either late
beneﬁt or late harm from treatment (2,3).
There are many barriers to obtaining long-term
follow-up. Research sponsors want results quickly;
commercial sponsors want to have their products
approved without delay; and even the National In-
stitutes of Health wants its investments in research to
have tangible results soon. Consequently, length of
follow-up may be a few weeks at most, and 1 year
of follow-up is often considered “long-term.” It is
Hlatky J A C C V O L . 6 4 , N O . 2 0 , 2 0 1 4
A Perspective on Short-Term Outcomes N O V E M B E R 1 8 / 2 5 , 2 0 1 4 : 2 1 0 9 – 1 0
2110expensive to follow up patients long-term, especially
if research staff must locate and contact each indi-
vidual over many years. It would be much simpler
and much less expensive to document outcomes
using routinely collected data, such as hospital
discharge and vital statistics records. My colleagues
and I recently showed that linking clinical trial data
with Medicare claims could provide a reliable method
to identify late cardiac events (4), which suggests that
long-term surveillance of clinical research subjects
using routine administrative data could be an ex-
tremely useful way to obtain extended follow-up in
clinical trials. Although it is conceptually simple to
follow up patients by linking research databases with
national administrative records, this is hugely difﬁ-
cult to accomplish in the United States. Our health-
care system is fragmented, with multiple payers;
many patients are uninsured; Americans are obsessed
with privacy and distrust the government and large
corporations; and regulations designed to protect
participants in high-risk clinical interventions have
been applied indiscriminately to low-risk research
studies.SEE PAGE 2101Other countries, such as Denmark, have universal
healthcare systems and different attitudes about
privacy and use of personal data for research pur-
poses. In this issue of the Journal, Danish researchers
highlight the value of their country’s willingness to
allow linkage of multiple healthcare and administra-
tive data resources and assess the long-term out-
comes of patients treated for an acute MI (5).
Pederson and associates nicely document the late
outcomes of primary percutaneous coronary inter-
vention (PCI) for acute MI (5). The survival curve
clearly shows 2 distinct phases, indicated by a clear
break in the slope of the curve at about 6 months of
follow-up. The early high-risk period is almostentirely attributable to cardiac mortality, which is not
surprising in a cohort of patients who have had an
acute MI. Successful primary PCI reduces but does not
eliminate the mortality of an acute MI. More subtly,
there is a treatment selection bias for primary PCI,
since patients with a serious noncardiac disease are
unlikely to be chosen, which reduces the risk of an
early noncardiac death.
After about 6 months, the survival curve ﬂattens
out as the early risk phase of the acute MI passes, and
the later-phase steady-state risk becomes evident. In
this later phase, cardiac mortality appears to be only
half of total mortality: patients with an acute MI
remain vulnerable to noncardiac disease, and some of
the same factors that put them at risk for an MI also
increase their risk for noncardiac death. Diabetes, for
instance, is a strong predictor of late mortality, only
some of which is cardiac. Lung disease and cancer
due to smoking also pose long-term risks to survivors
of an acute MI. The reduction in mortality from pri-
mary PCI can only be a short-term success, and in the
long term, other forces of mortality will come to the
fore.
One implication of these observations is that we
cannot rest on our laurels after successful treatment
of an acute MI. We need to recognize the factors, both
cardiac and noncardiac, that pose the greatest risk to
patients who survive an MI and initiate the therapies
and behavior changes that will reduce the risk of late
mortality. Long-term results matter, even for acute
illnesses and short-term therapies. We need to
develop methods to obtain long-term follow-up efﬁ-
ciently so we can document outcomes and identify
optimal strategies to reduce long-term risk.
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